Xbio stock price target

Shares Out (MIL) 2.00 mean rating - 1 analysts 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer. Stock split history for Xenetic Biosciences since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please CAR T platform technology engineered to target patient-specific tumor neoantigens.

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant  Stock analysis for Xenetic Biosciences Inc (XBIO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. platform technology engineered to target patient-specific tumor neoantigens,  View today's stock price, news and analysis for Xenetic Biosciences Inc. (XBIO). Barron's also provides information on historical stock ratings, target prices,  3 Feb 2020 On Friday, shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) Additionally, long-term investors are predicting the target price of $2.50,  Shares Out (MIL) 2.00 mean rating - 1 analysts 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer. Stock split history for Xenetic Biosciences since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please CAR T platform technology engineered to target patient-specific tumor neoantigens.

Latest stock price today and the US's most active stock market forums. Xenetic Biosciences (XBIO) stock price, charts, trades & the US's most popular discussion forums. Free forex prices…

XBIO | Xenetic Biosciences Inc. Stock Price & News - WSJ View the latest Xenetic Biosciences Inc. (XBIO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Xenetic Biosciences, Inc. - XBIO - Stock Price Today - Zacks Get the latest Xenetic Biosciences, Inc. XBIO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Xenetic Biosciences, Inc. - XBIO - Stock Price Today - Zacks XBIO is up 3.98 XBIO | Xenetic Biosciences Inc. Analyst Estimates ... Nov 07, 2019 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. MarketWatch Top Stories XBIO Stock Price and Chart — NASDAQ:XBIO — TradingView

Xenetic Biosciences Stock Quote. XBIO - Stock Price, News ...

The 1 analysts offering 12-month price forecasts for Xenetic Biosciences Inc The current consensus among 1 polled investment analysts is to Buy stock in  1 equities research analysts have issued 12-month price objectives for Xenetic Biosciences' stock. Their forecasts range from $2.50 to $2.50. On average, they  Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 242.51%. The high price target for XBIO is $2.50 and the low 

XBIO Stock Price & Charts | Xenetic Biosciences

XBIO - Xenetic Biosciences Stock Price - Barchart.com It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Xenetic Biosciences down 5% on underwhelming PolyXen data ... Jan 14, 2020 · Nano cap Xenetic Biosciences (XBIO -4.5%) slips on almost double normal volume on the heels of results from a Phase 1/2 clinical trial sponsored … XBIO Stock Price & Charts | Xenetic Biosciences

It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share.

Nasdaq: XBIO Enhancing Lives with Transformative Therapies Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. XBIO Stock Analysis: Price, Forecast, and News XBIO Stock Analysis Overview . What this means: InvestorsObserver gives Xenetic Biosciences Inc (XBIO) an overall rank of 32, which is below average. Xenetic Biosciences Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. XENETIC BIOSCIENCES, INC. : XBIO Stock Price | MarketScreener Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens.

XBIO Stock Price & Charts | Xenetic Biosciences Description: Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells XBIO Stock | XENETIC BIOSCIENCES Stock Price Today ... XBIO: Get the latest Xenetic Biosciences stock price and detailed information including XBIO news, historical charts and realtime prices. XBIO Stock Price Quote & News - Xenetic | Robinhood View the real-time XBIO price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Xenetic against related stocks people have also bought like OCGN, VISL, ONTX, and GHSI. 1,164 people own Xenetic on Robinhood on March 29, 2020.